

### **Amendments to the Drawings**

The attached sheet of drawings includes changes to FIG. 18 and replaces the original sheet that included FIG. 18. In FIG. 18, the incomplete reference character **236** has been corrected to read **236c**.

Attachment: Replacement Sheet

Annotated Sheet Showing Changes

## **SUPPORT FOR AMENDMENTS**

Claims 2, 34 and 35 are canceled without prejudice to their continued prosecution in a continuation and/or divisional application.

The amendments to the specification were made to correct typographical errors and are fully supported by the description in the specification and the drawings (e.g., page 22, line 20; page 25, line 2; FIGS. 12 and 14; etc.)

The amendments to claims 26, 29, 32, and 33 were made for clarification. The amendments to claims 1, 24, and 30 are fully supported by the description in the specification (e.g., page 28, lines 1-12; page 6, lines 19-21; etc.).

New claims 36, 37, and 38 are fully supported by the description in the specification (e.g., page 6, lines 19-21; page 16, lines 21-24; page 28, lines 14-16; claims 1-2; etc.)

The amendment to FIG. 18 was made to correct a typographical error and is fully supported by the description in the specification (e.g., page 25, lines 29-32).

No new matter has been added. Upon entry of this Response, claims 1, 3-33 and 36-38 are present and active in the application.

## REMARKS

By way of introduction, the claimed invention provides extraction devices and extraction methods for extracting analyte in living tissue through skin. As further explained below, the contact areas recited in independent claims 1, 19, 24, and 38 provide surprising and unexpected results. For example, as described in the specification, when the contact area of the electrode part and the extraction region of the skin exceeds about 50 mm<sup>2</sup>, as in conventional devices, the current becomes concentrated in part of the analyte transmission path (i.e., paths formed by the application of electrical energy to the skin, which enlarges macropores such as sweat glands, pores or the like, and intercellular micropores); as a result, a long time is required until a predetermined number of analyte transmission paths are formed, and the waiting time is increased before analyte can be extracted (specification, page 27, lines 27-33).

By contrast, the claimed extraction devices and extraction methods involve a smaller electrode extraction region and contact area than do conventional extraction devices and methods. Surprisingly and unexpectedly, these smaller areas make it more difficult for the current to become concentrated in only some of the analyte transmission paths. Therefore, the number of analyte transmission paths becomes stable in a short time after starting the current flow, and the amount of extracted analyte becomes stable in a shorter time; that is, the waiting time before extraction of the analyte is reduced (specification, page 9, lines 13-23).

As further explained below, none of the applied references, individually or in combination, teaches or suggests the claimed contact areas with "sufficient specificity" as to constitute an anticipation of the claims. Moreover, in view of the surprising and unexpected results provided by the claimed contact areas, none of the applied references, individually or in combination, would have rendered the claimed invention obvious.

## **Claim Rejections – 35 U.S.C. § 102**

1. The rejection of claims 2 and 35 under 35 U.S.C. § 102(b) as being anticipated by *Conn et al.* (U.S. Patent No. 6,438,414) have been rendered moot by the cancellation of these claims. Accordingly, withdrawal of this ground of rejection is respectfully requested.

2. The rejection of claims 1, 4-7, 13, 15, 17-22, 24-25, and 28-29 under 35 U.S.C. § 102(b) as being anticipated by *Conn et al.* is respectfully traversed. At a minimum, *Conn et al.* does not teach or suggest with sufficient specificity “a contact area with the skin of less than about 50 mm<sup>2</sup>,” as required by each of independent claims 1, 19, and 24.

*Conn et al.* describes transdermal sampling systems using electrodes “configured to provide an approximate electrode area of 0.3 to 1.0 cm<sup>2</sup>” (col. 18, lines 1-6)—a broad range that corresponds to an electrode area of 30 mm<sup>2</sup> to 100 mm<sup>2</sup>. Moreover, *Conn et al.* identifies a preferred area of 0.85 cm<sup>2</sup> (85 mm<sup>2</sup>), which lies well above the upper limit recited in the claimed invention. Applicants respectfully submit that the description in *Conn et al.* does not disclose the claimed contact areas with sufficient specificity for at least the reasons set forth below.

MPEP 2131.03(II) states the following:

When the prior art discloses a range which touches, overlaps or is within the claimed range, but no specific examples falling within the claimed range are disclosed, a case by case determination must be made as to anticipation. In order to anticipate the claims, the claimed subject matter must be disclosed in the reference with “sufficient specificity to constitute an anticipation under the statute.” What constitutes a “sufficient specificity” is fact dependent. If the claims are directed to a narrow range, the reference teaches a broad range, and there is evidence of unexpected results within the claimed narrow range, depending on the other facts of the case, it may be reasonable to conclude that the narrow range is not disclosed with “sufficient specificity” to constitute an anticipation of the claims. The unexpected results may also render the claims unobvious.

Applicants respectfully submit that the broad range described in *Conn et al.* lacks “sufficient specificity” to constitute an anticipation of the claimed invention under the

statute—particularly since the specific preferred area of 85 mm<sup>2</sup> lies well outside the claimed range. Moreover, in view of the surprising and unexpected results achieved by the claimed contact areas, Applicants respectfully submit that the claimed invention would not have been obvious in view of *Conn et al.*

Recent legal precedent from the U.S. Court of Appeals for the Federal Circuit (CAFC) reaffirms that a prior art disclosure of a claimed range must be with sufficient specificity in order to constitute an anticipation of a claim. *Atofina v. Great Lakes Chemical Corp.*, 441 F.3d 991 (Fed. Cir. 2006). The CAFC further rules that the disclosure of a range in a reference does not constitute disclosure of the endpoints of a claimed range nor of the intermediate points. *Atofina v. Great Lakes Chemical Corp.*, 441 F.3d at 1000.

Thus, inasmuch as *Conn et al.* does not teach or suggest the claimed contact areas with sufficient specificity, and in view of both the surprising and unexpected results achieved by the claimed contact area as well as the legal precedent establishing that the disclosure of a range does not constitute disclosure of the endpoints of a claimed range, Applicants respectfully submit that the claimed invention is neither anticipated by nor would have been obvious in view of *Conn et al.* Accordingly, withdrawal of this ground of rejection is respectfully requested.

3. The rejection of claims 19-20 and 22 under 35 U.S.C. § 102(e) as being anticipated by *Kim et al.* (U.S. Patent No. 6,736,777) is respectfully traversed. At a minimum, *Kim et al.* does not teach or suggest with sufficient specificity “a contact area with the skin of less than about 50 mm<sup>2</sup>,” as required by independent claim 19.

*Kim et al.* describes biosensor systems using platinum electrodes “configured to provide a geometric surface area of about 0.1 to 3 cm<sup>2</sup>” (col. 12, lines 6-28)—a broad range that corresponds to an electrode area of 10 mm<sup>2</sup> to 300 mm<sup>2</sup>. Moreover, *Kim et al.* identifies a most preferred area of 1 cm<sup>2</sup> (100 mm<sup>2</sup>), which lies well above the upper limit recited in the claimed invention. Applicants respectfully submit that the description in *Kim et al.* does not disclose the claimed contact areas with sufficient specificity for at least the reasons set forth above in the remarks addressing the rejection under 35 U.S.C. § 102(b).

Inasmuch as *Kim et al.* does not teach or suggest the claimed contact areas with sufficient specificity, and in view of both the surprising and unexpected results achieved by the claimed contact area as well as the legal precedent establishing that the disclosure of a range does not constitute disclosure of the endpoints of a claimed range, Applicants respectfully submit that the claimed invention is neither anticipated by nor would have been obvious in view of *Kim et al.* Accordingly, withdrawal of this ground of rejection is respectfully requested.

### **Claim Rejections – 35 U.S.C. § 103**

1. The rejection of claim 34 under 35 U.S.C. § 103(a) as being unpatentable over *Conn et al.* in view of *Avrahami et al.* (U.S. Patent Publication No. 2004/0230227) has been rendered moot by the cancellation of this claim. Accordingly, withdrawal of this ground of rejection is respectfully requested.

2. The rejection of claims 3, 8-11, and 26-27 under 35 U.S.C. § 103(a) as being unpatentable over *Conn et al.* in view of *Avrahami et al.* is respectfully traversed. At a minimum, *Conn et al.* and *Avrahami et al.* do not teach or suggest with sufficient specificity the range of contact area recited in independent claim 1.

As presently written, independent claim 1, from which rejected claims 3, 8-11, and 26-27 depend, and independent claim 24, from which rejected claims 26 and 27 depend, recite a range of contact areas between about 0.01 and about 50 mm<sup>2</sup>. *Conn et al.* does not disclose the contact areas recited in independent claims 1 and 24 with sufficient specificity for at least the reasons set forth above in the remarks addressing the rejection under 35 U.S.C. § 102(b).

*Avrahami et al.* describes an apparatus and method for transdermal drug delivery and analyte extraction in which the contact area of electrodes on the skin is a circle having a diameter between 10 and 100 microns (page 13, paragraph 188)—a range that corresponds to an electrode area of  $7.85 \times 10^{-5}$  to  $7.85 \times 10^{-3}$  mm<sup>2</sup>. This range is below the lower limit of 0.01 mm<sup>2</sup> presently recited in independent claims 1 and 24. As explained in the specification, “when the contact area of the electrode part and extraction region of

the skin is less than about 0.01 mm<sup>2</sup>, a long time is required to extract the amount of analyte necessary for analysis” (page 28, lines 1-4).

Thus, inasmuch as neither of *Conn et al.* nor *Avrahami et al.* teaches or suggests the claimed contact areas with sufficient specificity, and in view of the surprising and unexpected results achieved by the claimed contact area, Applicants respectfully submit that the claimed invention is neither anticipated by nor would have been obvious in view of these references, individually or in combination. Accordingly, withdrawal of this ground of rejection is respectfully requested.

3. The rejection of claim 32 under 35 U.S.C. § 103(a) as being unpatentable over *Conn et al.* in view of *Avrahami et al.* is respectfully traversed.

Independent claim 29, from which claim 32 depends, recites “placing a first extraction electrode part on the skin in which the analyte transmission paths are formed”; in other words, the first extraction electrode part is placed on the skin after analyte transmission paths have already been formed.

Neither *Conn et al.* nor *Avrahami et al.* teaches or suggest placing an extraction electrode part on skin in which analyte transmission paths have previously been formed, as required by independent claim 29. Thus, Applicants respectfully submit that claim 32 is neither anticipated by nor would have been obvious in view of these references, individually or in combination. Accordingly, withdrawal of this ground of rejection is respectfully requested.

4. The rejection of claim 14 under 35 U.S.C. § 103(a) as being unpatentable over *Conn et al.* in view of *Glikfeld et al.* (U.S. Patent No. 5,279,543) is respectfully traversed. At a minimum, *Conn et al.* and *Glikfeld et al.* do not teach or suggest with sufficient specificity the range of contact area recited in independent claim 1.

As presently written, independent claim 1, from which rejected claim 14 depends, recites a range of contact areas between about 0.01 and about 50 mm<sup>2</sup>. *Conn et al.* does not disclose the contact areas recited in independent claim 1 with sufficient specificity for at least the reasons set forth above in the remarks addressing the rejection under 35 U.S.C. § 102(b).

*Glikfeld et al.* describes devices for non-invasive sampling or delivery of substances in which electrodes range in size from  $1\mu\text{m}^2$  to  $400\text{ cm}^2$  (col. 11, lines 20-22)—a broad range that corresponds to an electrode area of  $1 \times 10^{-6}\text{ mm}^2$  to  $40,000\text{ mm}^2$ . Applicants respectfully submit that the description in *Glikfeld et al.* does not disclose the claimed contact areas with sufficient specificity for at least the reasons set forth above in the remarks addressing the rejection under 35 U.S.C. § 102(b).

Thus, inasmuch as neither of *Conn et al.* nor *Glikfeld et al.* teaches or suggests the claimed contact areas with sufficient specificity, and in view of the surprising and unexpected results achieved by the claimed contact area, Applicants respectfully submit that the claimed invention is neither anticipated by nor would have been obvious in view of these references, individually or in combination. Accordingly, withdrawal of this ground of rejection is respectfully requested.

5. The rejection of claims 12 and 16 under 35 U.S.C. § 103(a) as being unpatentable over *Conn et al.* in view of *Ackerman* (U.S. Patent Publication No. 2003/0208114) is respectfully traversed. At a minimum, *Conn et al.* and *Ackerman* do not teach or suggest with sufficient specificity the range of contact area recited in independent claim 1.

As presently written, independent claim 1, from which rejected claims 12 and 16 depend, recites a range of contact areas between about  $0.01$  and about  $50\text{ mm}^2$ . *Conn et al.* does not disclose the contact areas recited in independent claim 1 with sufficient specificity for at least the reasons set forth above in the remarks addressing the rejection under 35 U.S.C. § 102(b).

*Ackerman* describes methods of monitoring glucose levels using electrodes “configured to provide a geometric surface area of about  $0.1$  to  $3\text{ cm}^2$ ” (page 7, paragraph 67)—a broad range that corresponds to an electrode area of  $10\text{ mm}^2$  to  $300\text{ mm}^2$ . Moreover, *Ackerman* identifies a most preferred area of  $1\text{ cm}^2$  ( $100\text{ mm}^2$ ), which lies well above the upper limit recited in the claimed invention. Applicants respectfully submit that the description in *Ackerman* does not disclose the claimed contact areas with sufficient specificity for at least the reasons set forth above in the remarks addressing the rejection under 35 U.S.C. § 102(b).



Thus, inasmuch as neither of *Conn et al.* nor *Ackerman* teaches or suggests the claimed contact areas with sufficient specificity, and in view of the surprising and unexpected results achieved by the claimed contact area, Applicants respectfully submit that the claimed invention is neither anticipated by nor would have been obvious in view of these references, individually or in combination. Accordingly, withdrawal of this ground of rejection is respectfully requested.

### **Allowable Subject Matter**

The Examiner's indication that claims 21 and 23 contain allowable subject matter is noted with appreciation. However, since independent claim 19 is neither anticipated by nor would have been obvious in view of any of the cited references, individually or in combination, for at least the reasons set forth above, Applicants respectfully submit that claims 21 and 23, which depend from claim 19, are allowable as presently written.

The Examiner's further indication that claims 30-31 and 33 contain allowable subject matter is likewise noted with appreciation. However, since independent claim 29 is neither anticipated by nor would have been obvious in view of any of the cited references, individually or in combination, for at least the reasons set forth above, Applicant respectfully submits that claims 30-31 and 33, which depend from claim 29, are allowable as presently written.

### **New Claims**

New dependent claims 36-37 depend from independent claim 29. Inasmuch as independent claim 29 is neither anticipated by nor would have been obvious in view of any of the cited references for at least the reasons set forth above, Applicants respectfully submit that new dependent claims 36 and 37 are likewise neither anticipated by nor would have been obvious in view of these references.

Accordingly, Applicants respectfully submit that new claims 36-37 are in condition for allowance as presently written.

New independent claim 38 recites "a contact area with the skin of between about 0.01 and about 25 mm<sup>2</sup>—a range that is not taught or suggested with sufficient specificity by any of the cited references, individually or in combination. Accordingly,


Applicants respectfully submit that new claim 38 is in condition for allowance as presently written.

**Conclusion**

In view of the Amendment and Remarks set forth above, Applicants respectfully submit that the claimed invention is in condition for allowance. Early notification to such effect is earnestly solicited.

If for any reason the Examiner feels that the above Amendment and Remarks do not put the claims in condition to be allowed, and that a discussion would be helpful, it is respectfully requested that the Examiner contact the undersigned agent directly at (312)-321-4257.

Respectfully submitted,

  
\_\_\_\_\_  
Gregory H. Zayia  
Registration No. 48,059  
Agent for Applicants

BRINKS HOFER GILSON & LIONE  
P.O. BOX 10395  
CHICAGO, ILLINOIS 60610  
(312) 321-4200

Fig.18

